



**LAHIVE & COCKFIELD**  
L L P  
COUNSELLORS AT LAW  
28 STATE STREET  
BOSTON, MASSACHUSETTS 02109-1784  
TELEPHONE (617) 227-7400  
FAX (617) 742-4214  
lc@lahive.com

JOHN A. LAHIVE, JR. (1928-1997)  
THOMAS V. SMURZYNSKI  
RALPH A. LOREN  
GIULIO A. DeCONTI, JR.  
ELIZABETH A. HANLEY  
AMY BAKER MANDRAGOURAS  
ANTHONY A. LAURENTANO  
KEVIN J. CANNING  
JANE E. REMILLARD  
DeANN FORAN SMITH  
DEBRA J. MILASINCIC, Ph.D.  
WILLIAM A. SCOFIELD, JR.  
SIBLEY P. REPERT  
DAVID J. RIKKERS  
DAVID R. BURNS  
JOHN S. CURRAN  
SEAN D. DETWEILER  
MEGAN E. WILLIAMS, Ph.D.

LISA DIROCCO TYNER  
HATHAWAY P. RUSSELL \*  
MARIA LACCOTRIPE ZACHARAKIS, Ph.D.  
MERIDETH C. ARNOLD  
DANIELLE L. HERRITT  
EUIHOON LEE \*\*  
MANEESH GULATI  
CYNTHIA M. SOROOS  
PETER W. DINI, Ph.D.

**SENIOR COUNSEL**  
JAMES E. COCKFIELD

**OF COUNSEL**  
JEREMIAH LYNCH  
JEANNE M. DIGIORGIO  
CYNTHIA L. KANIK, Ph.D.  
JOHN D. LANZA

**PATENT AGENTS**  
THEODORE R. WEST  
JONATHAN M. SPARKS, Ph.D.  
ANDRINA WILLIAMS ZINK

**TECHNICAL SPECIALISTS**  
CATHERINE M. BISHOP  
JACOB G. WEINTRAUB  
CRISTIN E. HOWLEY, Ph.D.  
JILL ANN MELLO, Ph.D.  
DEBORAH L. NAGLE, Ph.D.  
ANNE JACQUELINE WIZEMAN, Ph.D.  
BRIAN C. TRINQUE, Ph.D.  
CHRISTOPHER R. COWLES, Ph.D.

\* Admitted in TX only  
\*\* Admitted in CT only

March 9, 2004

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Re: U.S. Patent Application No.: 10/671747  
For: INHIBITORS OF CYCLIN DEPENDENT KINASES AS ANTI-CANCER AGENT  
Inventors: Peter Martin Fischer *et al.*  
Filed: September 26, 2003  
Our Ref. No.: CCI-027CN

Dear Sir:

I enclose herewith for filing in the above-identified application the following:

1. Information Disclosure Statement;
2. PTO Form SB-08;
3. Copies of references cited in PTO Form SB-08 (6); and
4. A Return Postcard.

No additional costs are believed to be due in connection with the filing of this Information Disclosure Statement. However, please charge any necessary fees in connection with the enclosed statement to our Deposit Order Account No. 12-0080. For this purpose, a duplicate of this sheet is attached.


I hereby certify that this correspondence is deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450:


March 9, 2004

Date

Cynthia M. Soroos, Reg. No.

Respectfully submitted,  
LAHIVE & COCKFIELD, LLP

  
Cynthia M. Soroos  
Registration No. 53,623  
Attorney for Applicants



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Peter Martin Fischer *et al.*

Serial No.: 10/671747

Filed: September 26, 2003

For: INHIBITORS OF CYCLIN DEPENDENT  
KINASES AS ANTI-CANCER AGENT

Attorney Docket No.: CCI-027CN

Group Art Unit: 1614

Examiner: Not Yet Assigned

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450


Certificate of First Class Mailing (37 CFR §1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450 on the date set forth below.

March 9, 2004

Date of Signature and of Mail Deposit

By:

  
Cynthia M. Soroos  
Registration No. 53,623  
Attorney for Applicants

INFORMATION DISCLOSURE STATEMENT


Dear Sir:

Applicants and their Attorney are aware of the following publications and information, listed on the attached PTO Form SB-08, and in accordance with 37 CFR §1.97 hereby submit these publications for the Examiner's consideration. A copy of each cited publication is enclosed.

This statement is not to be interpreted as a representation that the cited publications are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any publication herein be construed *per se* as a representation that such publication is prior art. Moreover, Applicants understand that the Examiner will make an independent evaluation of the cited publications.

Under 37 CFR § 1.97(b)(3), no additional costs are believed to be due in connection with the filing of this disclosure. If, however, a first Office Action on the merits issues in this application bearing a mailing date prior to the date of this Information Disclosure Statement, please charge the appropriate fee as required under 37 CFR §1.17(p) to our Deposit Order Account No. 12-0080.

Respectfully submitted,  
LAHIVE & COCKFIELD, LLP

  
Cynthia M. Soroos  
Registration No. 53,623  
Attorney for Applicants

28 State Street  
Boston, MA 02109  
(617) 227-7400

Date: March 9, 2004

GAD/CLK/CMS/ipc  
Enclosures



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449A/B/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/671747
				Filing Date	September 26, 2003
				First Named Inventor	Peter Martin Fischer <i>et al.</i>
				Art Unit	1614
				Examiner Name	Not Yet Assigned
Sheet	1	of	1	Attorney Docket Number	CCI-027CN

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	A1	EP 0 233 461 A2	08-26-1987	AMERICAN CYANAMID COMPANY		
	A2	EP 0 588 762 A1	08-31-1992	CIBA GEIGY AG		
	A3	WO 95/09852 A1	04-13-1995	CIBA-GEIGY AG		
	A4	WO 97/19065 A1	05-29-1997	CELLTECH THERAPEUTICS LIMITED		
	A5	WO 00/39101 A1	07-06-2000	ASTRAZENECA UK LIMITED		
	A6	WO 02/46171 A2	06-13-2002	SIGNAL PHARMACEUTICALS, INC.		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
Examiner Signature		Date Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.